Compare MRKR & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRKR | HSCS |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | United States |
| Employees | 5 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 15.8M |
| IPO Year | 2010 | 2022 |
| Metric | MRKR | HSCS |
|---|---|---|
| Price | $1.21 | $4.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $10.00 | $8.00 |
| AVG Volume (30 Days) | 79.6K | ★ 133.7K |
| Earning Date | 05-14-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.61 | ★ 50.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,319.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $936.27 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.84 | $1.63 |
| 52 Week High | $2.46 | $4.35 |
| Indicator | MRKR | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 42.94 | 63.66 |
| Support Level | $1.07 | $1.88 |
| Resistance Level | $1.36 | $4.35 |
| Average True Range (ATR) | 0.10 | 0.36 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 17.47 | 59.66 |
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare setting, either via the MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via the MyoVista wavECG Device.